Revance Therapeutics Q3 Adj EPS $(0.55) Beats $(0.90) Estimate, Sales $56.78M Miss $60.38M Estimate
Portfolio Pulse from saritha@benzinga.com
Revance Therapeutics reported Q3 losses of $(0.55) per share, beating the analyst consensus estimate of $(0.90) by 38.89%. However, the company's quarterly sales of $56.78 million missed the analyst consensus estimate of $60.38 million by 5.97%. This represents a 52.99% increase in losses and a 95.68% increase in sales compared to the same period last year.
November 08, 2023 | 9:39 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Revance Therapeutics reported better than expected Q3 EPS but missed on sales. This mixed result could lead to volatility in the stock price.
Revance Therapeutics reported a better than expected EPS, indicating improved profitability. However, the company missed on sales, which could be a sign of slowing demand or operational inefficiencies. This mixed result could lead to uncertainty and volatility in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100